CHMP maintains negative opinion of Santhera's Sovrima
This article was originally published in Scrip
Executive Summary
The EMEA's CHMP has informally advised Santherathat it would maintain its negative opinion on the company's marketing authorisation application for lead product, Sovrima (idebenone), to treat Friedreich's Ataxia.